Wintermute is Now Recruiting Patients for the ZosterEase Phase Ib Clinical Trial. Read more here.
Wintermute Biomedical raises $1.3 million USD, exceeding its target, to expand its Phase Ib trial and accelerate shingles treatment advancements.
Wintermute Biomedical is thrilled to announce the successful completion of a $1.3 million USD bridging raise, exceeding the initial target of $1 million. This milestone, achieved in December 2024, reflects strong investor confidence and brings the total funds raised to support the company’s Phase Ib trial to $2.5 million USD.
The additional funding will be instrumental in expanding the Phase Ib trial, which will assess the safety and proof-of-concept efficacy of Solexan™ in shingles patients. This expansion includes the opening of new sites in New Zealand to accelerate patient recruitment. The expanded trial is a critical step in Wintermute’s mission to deliver groundbreaking solutions for shingles treatment, with continued progress of the program planned well into 2025.
The campaign garnered support from both new and existing investors, highlighting a growing network of advocates for Wintermute’s innovative work.
Dr. Tom Rau, CEO of Wintermute Biomedical, expressed his gratitude, stating, “We’re so grateful to have an amazing network of supportive investors. Having people who believe in our product and our vision to help people with shingles is a testament to the important work the team is doing. It’s great to have investors who believe in the cause and can see the vision for what we want to achieve.”
Wintermute’s revolutionary antimicrobial technology and dedication to improving patient outcomes continue to drive its success. The company remains committed to advancing its Solexan™ for shingles program and bringing innovative therapies to patients worldwide.
To find out more about our Solexan™ for shingles program and our Phase Ib trial, click here.